Telesis Bio Inc., a leader in DNA and mRNA synthesis solutions, has announced a licensing agreement with Regeneron Pharmaceuticals, Inc. to implement the Gibson SOLA™ platform at Regeneron's R&D core facilities. This innovative platform is designed to enhance on-site DNA and gene synthesis, significantly reducing the timeline for therapeutic research and drug development. The Gibson SOLA platform enables fully-enzymatic, overnight synthesis of high-fidelity DNA and mRNA, allowing for faster iteration and improved data security by eliminating the need for external service providers. This agreement marks an industry trend towards internalizing synthetic biology capabilities to accelerate drug discovery and development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.